Releases Details
Director Dealings and Issue of Equity
Released : February 19, 2021 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings and Issue of Equity
Total Voting Rights
Following the Exercise and Sale, Mr Brooke's holding of Common Stock remains unchanged at a total of 50,302 Common Stock, representing 0.1% of the issued share capital of the Company. Mr Brooke holds a further 128,500 options over Common Stock.
Total voting rights
The new Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the issue of the New Common Stock and following the recent issue of an additional 597,877 new Common Stock to non-PDMRs in satisfaction of the exercise of share options, is 84,555,946 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 74,325,857; the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 9,900,089 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Will Brooke |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non Executive Director |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
54930053YHXULRFCU991 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Exercise of options and Sale of Common Stock |
|
|
b) |
Identification Code |
US57777K1060 |
|
|
c) |
Nature of the transaction |
Exercise of options and Sale of Common Stock by PDMR |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
N/A
|
40,900 (option exercise) 40,900 (sale of common stock) |
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
|
f) |
Date of the transaction |
18 February 2021 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|
For further information, please contact:
|
|
|
||||||||
|
|
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL, MXCN) and is headquartered in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
